NAD supplements sold today, primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), have not been shown to cause liver damage in the clinical trials conducted so far. A meta-analysis pooling data from multiple randomized trials found no significant changes in standard liver enzymes after supplementation. But the question deserves more than a clean bill of health, because the liver sits at the center of NAD metabolism, and earlier forms of NAD-boosting compounds did cause serious liver injury. The story of NAD and the liver is more layered than supplement marketing or casual fear would suggest.
Why the Liver Is Central to NAD Metabolism
Your liver is the body’s main factory for producing NAD+. The process of building NAD+ from scratch, using the amino acid tryptophan, happens almost exclusively in the liver and, to a smaller degree, the kidneys. About 95% of circulating nicotinamide (the form of vitamin B3 your cells use most) is released by the liver, making it the supply depot for every other organ in the body.1Signal Transduction and Targeted Therapy. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential This means the liver processes a huge share of whatever NAD precursor you swallow. It is both the organ most likely to benefit from boosting NAD+ and, in theory, the organ most exposed to any downstream problems from doing so.
When you take an oral NR or NMN supplement, much of it doesn’t even reach your bloodstream as NR or NMN. Gut bacteria break down a large fraction of these precursors into nicotinic acid, which then travels to the liver and gets built back up into NAD+ through a different pathway.2PubMed Central. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD(+) synthesis via enterohepatic circulation The liver, in other words, is doing heavy lifting regardless of which precursor you choose. That makes its safety profile worth examining carefully.
The Niacin Shadow
Much of the anxiety around NAD supplements and liver damage traces back to niacin, also known as nicotinic acid or vitamin B3. Niacin was prescribed for decades to lower cholesterol, and at high doses it earned a reputation for causing liver injury. The worst offender was the sustained-release formulation. In one well-known comparison trial, none of the patients taking immediate-release niacin developed liver toxicity, while roughly half of those taking the sustained-release version did. Most patients on the sustained-release form couldn’t even complete the study because of gastrointestinal symptoms, fatigue, and rising liver enzymes.3JAMA. A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients
Case reports from that era describe severe outcomes, including patients who developed acute liver failure with dangerously low blood pressure and metabolic collapse after switching from a well-tolerated immediate-release niacin to a sustained-release preparation.4The American Journal of Medicine. Hepatotoxicity associated with sustained-release niacin The problem was dose-dependent. Liver enzyme elevations were common above about 2 grams per day of sustained-release niacin, and the damage could progress to a pattern resembling fatty liver disease at the cellular level.5PubMed Central. Niacin‐Induced Anicteric Microvesicular Steatotic Acute Liver Failure
This history matters because niacin is a NAD precursor, and people sometimes lump all NAD-boosting compounds together. But NR and NMN are chemically distinct from niacin, enter NAD metabolism through different routes, and have not produced the same pattern of liver toxicity in any published trial. Treating them as interchangeable with high-dose sustained-release niacin is a mistake the evidence doesn’t support.
What Human Trials Show for NR
Nicotinamide riboside is the most extensively studied NAD precursor in randomized human trials. In an eight-week trial of healthy overweight adults receiving NR at doses up to 1,000 mg per day, researchers tracked the full panel of liver enzymes (AST, ALT, GGT, and bilirubin) at multiple time points. There were no statistically significant differences between the NR group and placebo on any clinical chemistry parameter.6Scientific Reports. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
A larger safety trial (NR-SAFE) tested NR at 3,000 mg per day in people with Parkinson’s disease, a dose well above what most consumer supplements provide. Aside from a small rise in homocysteine levels (more on that later), no abnormal changes in clinical lab values were reported.7PubMed Central. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease That’s a reassuring signal, because 3,000 mg per day is roughly three to six times what most supplement labels recommend.
Animal toxicology data back this up. A 90-day study in rats tested synthetic NR at doses up to 1,200 mg per kilogram per day with no mortality, no adverse clinical pathology findings, and no notable tissue damage. The no-observed-adverse-effect level was set at 500 mg/kg/day for males and 1,200 mg/kg/day for females.8PubMed. Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm Scaling those numbers down to humans provides a wide safety margin at typical supplement doses.
What Human Trials Show for NMN
NMN has a shorter track record in clinical research, but the available data tell a similar story. A multicenter, dose-ranging trial tested NMN at 300, 600, and 900 mg per day in healthy middle-aged adults. No abnormalities were observed in clinical lab parameters across any dose group, and the treated groups were not statistically different from placebo on liver-relevant measures.9PubMed Central. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
A separate 12-week trial in healthy subjects receiving 250 mg per day of NMN specifically looked at liver function markers. AST, ALT, and gamma-GTP all remained within normal range, with no significant difference between NMN and placebo.10Frontiers in Nutrition. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects These are small studies, and 12 weeks isn’t forever, but they consistently point in the same direction: no liver alarm bells at ordinary supplement doses.
The Meta-Analysis That Pulls It Together
The strongest evidence comes from a systematic review and meta-analysis that pooled results across multiple randomized controlled trials of NAD precursor supplementation. The pooled analysis found that ALT, AST, and ALP levels were not significantly changed after supplementation compared to placebo. The authors concluded that NAD precursor supplementation does not appear to have a significant effect on liver enzymes. If these supplements were causing meaningful liver stress at typical doses, this kind of pooled analysis is exactly where you’d expect the signal to show up. It didn’t.
The Counterintuitive Finding: NAD May Protect the Liver
Here’s where the story gets interesting. Far from harming the liver, boosting NAD+ levels has shown protective effects against liver disease in animal models. In mice fed a high-fat diet to induce fatty liver disease, NR treatment improved hepatic steatosis (fat accumulation in the liver), reduced inflammation, improved insulin resistance and mitochondrial function, and decreased fibrosis.11PubMed Central. NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin NAD precursor supplementation has been validated as effective in mouse models of metabolic dysfunction-associated steatotic liver disease (the current term for what used to be called nonalcoholic fatty liver disease).12iScience. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota
The anti-fibrosis effect deserves particular attention. Liver fibrosis, the scarring that leads to cirrhosis, is driven by the activation of hepatic stellate cells. NR has been shown to inhibit stellate cell activation in both mouse and human cell cultures, and to reduce fibrosis in diet-induced mouse models.13Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis NMN showed a similar effect, suppressing stellate cell activation and protecting against chemically induced liver fibrosis in mice.14PubMed. NAMPT-mediated NAD(+) biosynthesis suppresses activation of hepatic stellate cells and protects against CCl(4)-induced liver fibrosis in mice NAD repletion has been associated with decreased stellate cell activation and decreased fibrosis more broadly.15PubMed. NAD(+) and NAFLD – caution, causality and careful optimism
The caveat: nearly all of this evidence comes from mouse models. The handful of human trials that have looked at NAD precursors in people with obesity found only modest effects. The leap from “reversed fatty liver in mice” to “will fix your liver” in humans hasn’t been made yet, and researchers have urged careful optimism rather than premature enthusiasm.
Where the Concerns Get More Specific
If the broad clinical picture looks reassuring, a few narrower risks are worth understanding.
The 1-MNA Problem With Alcohol
When your body processes nicotinamide (the breakdown product that all NAD precursors eventually produce), it creates a metabolite called 1-methylnicotinamide (1-MNA). In mice, giving 1-MNA alongside chronic alcohol significantly worsened alcohol-induced fatty liver. The metabolite amplified fat accumulation, ramped up ER stress markers in liver cells, and increased the expression of genes involved in lipid production.16Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids. 1-Methylnicotinamide promotes hepatic steatosis in mice: A potential mechanism in chronic alcohol-induced fatty liver disease This is one mouse study, not a definitive verdict, but the implication is straightforward: if you drink heavily and take high doses of NAD precursors, the downstream metabolites might not be neutral for your liver. This interaction hasn’t been studied in humans yet, so caution seems warranted.
Methyl Donor Drain
Converting nicotinamide into 1-MNA requires a methyl group, donated by a molecule called SAM (S-adenosylmethionine). When the enzyme responsible for this reaction (NNMT) is overactive, SAM levels drop and the balance between methyl donors shifts.17PubMed. Nicotinamide N-Methyltransferase Interacts with Enzymes of the Methionine Cycle and Regulates Methyl Donor Metabolism In theory, flooding the body with NAD precursors could accelerate this drain, especially at high doses. Some longevity enthusiasts co-supplement with trimethylglycine (betaine) or other methyl donors to compensate, though there’s no clinical trial confirming this is necessary or that methyl depletion from standard supplement doses causes harm in humans. The homocysteine bump observed in the NR-SAFE trial at 3,000 mg per day is at least loosely consistent with methyl donor stress, since homocysteine rises when methyl recycling is impaired.
Intravenous NAD Versus Oral Supplements
The booming “NAD drip” industry introduces a different set of considerations. A retrospective pilot study comparing intravenous NAD+ and intravenous NR found that liver enzymes (ALT and AST) did not change significantly from baseline in either group after 30 days. Interestingly, alkaline phosphatase actually decreased in the IV NAD+ group.18PubMed Central. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
However, a separate randomized pilot study found that IV NAD+ produced an increase in white blood cell counts and neutrophils, suggesting some kind of inflammatory response, while IV NR did not trigger the same reaction.19medRxiv. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults IV delivery bypasses the gut entirely, which means the liver receives a concentrated bolus without the gradual processing that happens during oral absorption. The research here is still very preliminary, and IV NAD+ sits in a regulatory gray zone in many countries. If you’re considering IV infusions, the safety data is thinner than for oral supplements, and the inflammatory signal deserves attention.
When Timing Might Matter
A 2023 mouse study raised an unexpected variable: the time of day you take an NAD precursor may influence how the liver responds. Researchers gave obese mice NAD+ either before their active phase (equivalent to morning for humans) or before their rest phase (evening). The mice treated before their active phase showed improvements in body weight, glucose tolerance, and liver fat, with reduced hepatic inflammation. But mice treated before the rest phase had a weaker or even compromised response to treatment.20Nature Communications. Time-of-day defines NAD+ efficacy to treat diet-induced metabolic disease by synchronizing the hepatic clock in mice NAD metabolism in the liver is tightly linked to circadian rhythms, so the finding makes biological sense. It hasn’t been replicated in humans, but if you’re already taking an NAD precursor, taking it in the morning rather than at night is a low-cost bet that aligns with the available evidence.
The Cancer Question
A separate concern that surfaces in longevity circles is whether flooding your body with NAD+ could fuel cancer. The reasoning is that cancer cells have high energy demands, and NAD+ is central to cellular energy production. Researchers have flagged this as a theoretical risk, noting that more work is needed to determine whether elevating NAD+ levels could increase the potential for tumor growth or other age-related pathology.21PubMed Central. Nicotinamide adenine dinucleotide and the sirtuins caution: Pro-cancer functions This concern applies to the whole body, not just the liver, but it’s relevant here because the liver is a common site for metastatic cancer and already handles the bulk of NAD processing. There is no clinical evidence that NAD supplements promote liver cancer in humans. But the question is genuinely open, and the mechanistic logic is real enough that researchers keep raising it.
Who Should Be Cautious
The safety data we have comes overwhelmingly from healthy or moderately overweight adults without pre-existing liver disease. If you already have compromised liver function, the picture is less clear. The liver’s capacity to process NAD precursors and their metabolites depends on having functional enzymatic machinery, adequate bile flow, and intact clearance systems. People with cirrhosis, active hepatitis, or advanced fatty liver disease have not been well-represented in NAD supplement trials.
Drug interactions also remain understudied. NAD metabolism intersects with pathways affected by common medications, including those processed by the liver’s cytochrome P450 system. If you’re taking statins, metformin, or other drugs that are heavily liver-metabolized, there’s no evidence that adding an NAD precursor at typical supplement doses causes a problem, but there’s also very little research specifically examining the combination. People on medication for liver conditions, or those with significantly elevated liver enzymes from any cause, would be reasonable to get periodic bloodwork if they choose to supplement.
One practical note: over-the-counter NAD supplements are not regulated with the same rigor as pharmaceuticals. Purity, actual dose, and the presence of contaminants vary between brands. Some of the liver concerns that surface anecdotally may have more to do with what else is in the capsule than with the NAD precursor itself. Choosing products that have been third-party tested and manufactured under recognized quality standards reduces this variable, even if it doesn’t eliminate it entirely.
How Gut Bacteria Change What Reaches Your Liver
One of the more surprising recent findings is that your gut microbiome substantially rewrites whatever NAD precursor you swallow before it reaches the liver. Research has shown that only a small portion of orally administered NMN and NR is directly absorbed from the small intestine. The majority gets broken down by gut bacteria into nicotinic acid, which is then absorbed, processed through gut cells, and transported to the liver as a different set of intermediates.2PubMed Central. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD(+) synthesis via enterohepatic circulation Earlier work demonstrated that gut bacteria deamidate dietary nicotinamide to nicotinic acid, which then enters a pathway that significantly contributes to hepatic NAD production.22Cell Metabolism. Gut Microbiota-Mediated Deamidation of Nicotinamide Riboside and Nicotinamide Enhances Hepatic NAD+ Biosynthesis
This means two people taking the same NR or NMN pill may deliver quite different metabolites to their livers, depending on their gut flora. It also means the liver often ends up processing something closer to nicotinic acid than to the supplement advertised on the label. From a safety standpoint, the nicotinic acid pathway (sometimes called the Preiss-Handler pathway) is well-characterized and distinct from the mechanisms behind high-dose sustained-release niacin toxicity, where the problem was related to the formulation’s release kinetics rather than nicotinic acid itself at moderate levels. Still, the role of the microbiome adds a layer of individual variability that clinical trials averaging results across groups may not fully capture.